EUVIMEDEUVIMED entdecken
Open Access

Clinical Benefit of Fixed‐Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia

Chia-Pin Lin iD, Tzyy-Jer Hsu, Ying-Chang Tung iD, Fu-Chih Hsiao iD, Shing-Hsien Chou, Yu-Sheng Lin iD, Shao-Wei Chen iD, Pao-Hsien Chu iD

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.123.033780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Chia-Pin Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, College of Medicine Chang Gung University Taoyuan Taiwan. Hauptthemen laut MEDLINE: Amlodipine, Hypercholesterolemia, Hypertension, Atorvastatin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypertension and hypercholesterolemia are important risk factors for cardiovascular disease, and treatment with fixed‐dose combination (FDC) regimens is recommended by current guidelines. However, the clinical outcomes of different FDC dosages remain unknown. This study aimed to examine the clinical outcomes of FDC regimens and the free combination of amlodipine and atorvastatin at different dosages. Methods and Results Patients with concurrent hypertension and hypercholesterolemia treated daily with an FDC of 5 mg amlodipine and 10 mg atorvastatin (5/10 fixed group), and FDC of 5 mg amlodipine and 20 mg atorvastatin (5/20 fixed group), or free combination of 5 mg amlodipine and 20 mg atorvastatin (5/20 free group) were identified from the National Health Insurance Research Database of Taiwan. The primary outcome was the composite cardiovascular outcomes, including cardiovascular death, acute myocardial infarction, stroke, and coronary intervention. A total of 9095 patients were eligible for inclusion. The incidence of primary outcome per 1000 person‐years was 16.6 in the 5/10 fixed group, 12.6 in the 5/20 fixed group, and 16.5 in the 5/20 free group (5/20 fixed versus 5/20 free: hazard ratio [HR], 0.76 [95% CI, 0.64–0.91]; 5/20 fixed versus 5/10 fixed: HR, 0.76 [95% CI, 0.63–0.90]).

Conclusions

Among patients with concomitant hypertension and hypercholesterolemia, treatment with an FDC of amlodipine and high‐dose atorvastatin led to a lower risk of a composite of cardiovascular outcomes than treatment with the free combination or a similar FDC with a lower dose of atorvastatin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmlodipineHypercholesterolemiaHypertensionAtorvastatinDrug CombinationsHeptanoic AcidsPyrrolesHumansMaleFemaleMiddle AgedAgedTaiwanTreatment OutcomeAntihypertensive AgentsRetrospective StudiesHydroxymethylglutaryl-CoA Reductase InhibitorsAnticholesteremic AgentsCalcium Channel BlockersBlood Pressure

Stichwörter der Autor:innen

amlodipineatorvastatinfixed‐dose combinationhypercholesterolemiahypertension

Substanzen

AmlodipineAtorvastatinDrug CombinationsAntihypertensive Agentsamlodipine, atorvastatin drug combinationHydroxymethylglutaryl-CoA Reductase InhibitorsAnticholesteremic AgentsCalcium Channel BlockersHeptanoic AcidsPyrroles

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, College of Medicine Chang Gung University Taoyuan Taiwan.
  • School of Medicine National Tsing Hua University Hsinchu Taiwan.
  • Graduate Institute of Clinical Medical Science, College of Medicine Chang Gung University Taoyuan Taiwan.
  • Department of Internal Medicine, Taoyuan Chang Gung Memorial Hospital, College of Medicine Chang Gung University Taoyuan Taiwan.
  • Healthcare Center Chang Gung Memorial Hospital Taoyuan Taiwan.
  • Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, College of Medicine Chang Gung University Taoyuan Taiwan.

ORCID-Profile: Chia-Pin Lin, Ying-Chang Tung, Fu-Chih Hsiao, Yu-Sheng Lin, Shao-Wei Chen, Pao-Hsien Chu

Zitieren

APA

Lin, C. P., Hsu, T. J., Tung, Y. C., Hsiao, F. C., Chou, S. H., Lin, Y. S., Chen, S. W., & Chu, P. H. (2024). Clinical Benefit of Fixed‐Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.033780

Vancouver

Lin CP, Hsu TJ, Tung YC, Hsiao FC, Chou SH, Lin YS, et al. Clinical Benefit of Fixed‐Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.033780

BibTeX
@article{Lin2024,
  author = {Lin, Chia-Pin and Hsu, Tzyy-Jer and Tung, Ying-Chang and Hsiao, Fu-Chih and Chou, Shing-Hsien and Lin, Yu-Sheng and Chen, Shao-Wei and Chu, Pao-Hsien},
  title = {Clinical Benefit of Fixed‐Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.123.033780}
}
Kostenlos starten →